{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.2"}]}],"title":"13q- (n=112)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.5"}]}],"title":"t (4;14) (n=38)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.2"}]}],"title":"17p- (n=31)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.5"}]}],"title":"Other (n=104)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.3"}]}],"title":"No changes (n=102)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"334"}],"units":"Participants"}],"description":"Response rate was defined as the percentage of participants with response of combined CR+PR according to the EBMT criteria. As per the EBMT criteria, CR is defined as the absence of serum and urine monoclonal paraprotein and no increase in size or number of lytic bone lesions; PR is defined as not all CR criteria and 50 percentage or more reduction in serum monoclonal paraprotein. Percentage of participants with complete or partial response that carried the indicated cytogenetic marker is reported. Same participant could count in more than one category due to multiple responses possible","groups":[{"description":"Cyclophosphamide + Bortezomib + Dexamethasone for three 21-day cycles","id":"OG000","title":"Cyclophosphamide + Bortezomib + Dexamethasone"}],"paramType":"NUMBER","populationDescription":"Efficacy analysis set. N (number of participants analyzed) signifies participants with complete or partial response. \"n\" signifies number of participants who were evaluable for each specified category (participants that carried the indicated cytogenetic marker).","reportingStatus":"POSTED","timeFrame":"Up to Day 63","title":"Percentage of Participants With Complete Response + Partial Response in Relation to Cytogenetic Subgroups (Efficacy Set)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}